Ibex Medical Analytics has launched Ibex 4, an AI-powered pathology platform with expanded end-to-end breast cancer diagnostic workflows, zero-click IHC tools, and enhanced lab integration capabilities for increased efficiency.
The FDA has granted Breakthrough Device Designation to Breath Diagnostics Inc.'s OneBreath, a breath-based test that assesses postoperative pneumonia risk in cardiac surgery patients using a single preoperative sample.
The NeXT Personal molecular residual disease test can now be used for surveillance of patients with Stage I to III non-small cell lung cancer.
Ambry Genetics supported a new study evaluating 6,718 PALB2 gene variants using MAVEs, advancing risk assessment for hereditary breast and pancreatic cancer.
Read More
GRAIL has submitted an FDA premarket approval application for its Galleri multi-cancer early detection test, supported by data from more than 25,000 participants in US and UK clinical trials.
Read More
A new study found the assay detected immunotherapy response in advanced cancer patients a median of 23 days after treatment—over five months earlier than imaging.
Read More
Valley Diagnostics has secured exclusive global rights to develop point-of-care lateral flow tests for prostate cancer, lung cancer, and animal diseases, with product rollout planned for 2026.
Read More
A real-world study of 111,080 participants found the Galleri multi-cancer blood test achieved a 0.91% cancer detection rate and 87% accuracy in predicting tumor origin.
Read More
Researchers at Mass General Brigham have developed a blood test that predicts tarlatamab response in small cell lung cancer, showing 85% sensitivity and 100% specificity.
Read More
The FDA has approved a companion diagnostic for identifying BRAF V600E-mutant metastatic colorectal cancer patients eligible for encorafenib combination therapy.
Read More
Researchers at Baylor College of Medicine have identified four new protein markers that improve detection of triple-negative breast cancer cells in blood, potentially enhancing the accuracy of liquid biopsy tests, according to a recent study.
Read More
Lucid Diagnostics has secured a VA contract for its EsoGuard Esophageal DNA Test, expanding access to esophageal precancer screening for more than 9 million veterans through the federal supply schedule at Medicare-aligned pricing.
Read More
The collaboration will utilize Guardant’s liquid biopsy portfolio for the development of companion diagnostics for drug approvals.
Read More
BillionToOne has partnered with Epic to integrate its UNITY Complete prenatal and Northstar oncology tests into Epic’s EHR system, enabling direct ordering and results delivery for healthcare providers.
Read More
A study reports that post-treatment circulating tumor DNA levels may better predict recurrence in HER2-positive breast cancer patients than current pCR measures.
Read More
Labcorp has expanded its MRD testing portfolio with new personalized panels for breast and lung cancer and nationwide whole-genome MRD testing for stage III colon cancer, enabling earlier detection of recurrence via ctDNA analysis.
Read More
CITCCA data demonstrate more than 40% of high-risk stage I–III colorectal patients harbor molecular residual disease at clinical landmark, detectable only with ultrasensitive ctDNA testing.
Read More
The collaboration will combine New Day’s liquid biopsy technology with Daisy Genomics’ physics-based sequencing platform to advance early CRC screening.
Read More